A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-11-01

Study Completion Date

2005-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK0683 in patients with advanced cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)

NCT00907738

Advanced Cancer

COMPLETED PHASE2

A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048)

NCT00373490

Tumors

COMPLETED PHASE1

A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029)

NCT00127127

Tumors

COMPLETED PHASE1

A Study of MK0731 in Patients With Advanced Solid Tumors (0731-002)(COMPLETED)

NCT00104364

Cancer

COMPLETED PHASE1

A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001)

NCT01358331

Tumor, Solid

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer, Advanced

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

MK0683

Group Type EXPERIMENTAL

vorinostat (MK0683 )

Intervention Type DRUG

Panel A: vorinostat 400 mg capsules once daily on Days 1, 5, 7-28

Total treatment period is 28 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

vorinostat (MK0683 )

Panel A: vorinostat 400 mg capsules once daily on Days 1, 5, 7-28

Total treatment period is 28 days

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Zolinza

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients 18 years or older
* Must agree to consume high fat meal and agree to fasting conditions
* Limit alcohol consumption

Exclusion Criteria

* Patient has a history of drug or alcohol abuse within 5 years of start of study
* Patient is known to have HIV
* Patient has participated in another investigational study within 4 weeks of start of study
* Patient cannot stop taking certain medications or herbal remedies
* Patient will require immunologic, radiation, surgery, or chemotherapy during the study
* Patient requires frequent blood transfusions
* Female patient is pregnant or nursing
* Patient has an active Hepatitis B or C infection

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No